Chargement...
Chargement...
Rouen, France, January 9, 2024 – Robocath, a company that designs, develops and markets innovative robotic solutions to treat cardiovascular diseases, today announces the granting of a marketing authorization to distribute its R-One robotic platform in China. This was issued on December 8, by the Chinese National Medical Products Administration (NMPA); making it the first vascular robotic platform to be granted approval in China.
This approval is based in part on the outstanding results achieved in Cathbot’s multicenter clinical trial involving 145 patients in China. Cathbot is the joint venture between Robocath and MedBot, the robotic subsidiary of the MicroPort Scientific Corporation. The full trial data will be published in the coming weeks via a special statement.
“I’m delighted that R-One is coming to the Chinese market. This approval will boost our commercial growth, allowing more people to take advantage of more precise endovascular procedures under improved working conditions. The interventional cardiologists who use R-One will benefit from complete protection from X-rays and increased precision during the procedure. Our next step is to develop a solution that can perform angioplasty remotely, to provide better and efficient medical care for vascular diseases patients all over the country,” said Chao He, president of MedBot.
“This approval to start the commercialization of our technology in China symbolizes the success of our joint venture (Cathbot) we established together with our partner MicroPort-MedBot in 2020. I would like to thank all the collaborators from the different entities involved in this process who contributed their expertise, know-how and high energy to make this major project a reality. China today has a large number of patients suffering from coronary heart disease. By 2030, the number of coronary angioplasties in China is set to triple, to 3.2 million, driven by population growth, an aging population and the increased prevalence of certain risk factors. This all makes China the world’s largest and most dynamic vascular market! The NMPA approval is therefore an outstanding news for Robocath. We are delighted to have taken this key step in our international growth strategy,” said Lucien Goffart, CEO of Robocath.
“We are extremely proud to have received approval for our platform in this highly strategic market. R-One is currently the only vascular robotic platform available in China. We share our partner’s deeply held conviction that the future of interventional medicine lies in robotics and artificial intelligence. Given this major achievement and the operational effectiveness of the partnership, we are now confident that we have everything we need to build a world-leading presence in vascular robotics. Other projects are already underway, including the development of remote treatment. The first human trials took place a few months ago and were very promising,” said Philippe Bencteux, president and founder of Robocath.
ABOUT MEDBOT
Founded in 2014, MedBot develops intelligent surgical robotic systems and solutions. It is committed to meeting the most cutting-edge development needs of minimally invasive surgery and innovatively providing integrated intelligent surgical solutions that can save patients’ lives or improve their quality of life. Following years of research and development, innovation and industrial accumulation, MedBot has grown to become a medical robot company that masters the underlying technology in the entire chain. With its three flagship products in the three major segments, namely the Toumai™ laparoscopic surgical robot, Skywalker™ joint replacement surgical robot and DFVision™ three-dimensional electronic laparoscope and having entered the special approval procedure (Green Path) for innovative medical devices at the National Medical Products Administration (NMPA), Medbot is the only surgical robot company with three ‘Green Path’ grants in the People’s Republic of China (PRC). Its current business covers five areas, including endoscopy, orthopedics, vascular intervention, natural orifice and percutaneous puncture.
ABOUT MICROPORT
MicroPort® was founded in 1998 in ZJ Hi-Tech Park in Shanghai China, where a group of dedicated individuals joined together in the common belief that advancements in medical technology could transform patients’ lives in China and around the globe. Over the last two decades, MicroPort® has taken important steps towards fulfilling its mission of providing access to the best means of prolonging and reshaping lives. Today, MicroPort® is focused in covering ten major areas, including Cardiovascular Intervention & Structural Heart Diseases, Electrophysiology & Cardiac Rhythm Management, Orthopedics & Soft Tissue Repair, Endovascular & Peripheral Vascular Diseases, Neurovascular Intervention & Neurosciences, Life Sciences (Endocrine Management), Surgical Devices & Medical Robotics, Urology & Gynecology & Respiratory & Gastroenterology, Aesthetics & Rehabilitation, and In vitro Diagnostics & Medical Imaging. Thanks to over 300 MicroPort® devices currently approved for use in nearly 10,000 hospitals worldwide, one of our devices is used every six seconds. With a vast global footprint of R&D and manufacturing sites (Shanghai; Memphis, TN in the United States; Clamart in France; Saluggia in Italy; Santo Domingo in the Dominican Republic), a strong focus on technology innovation with over 4,700 patent applications, and a global workforce of over 7,000 employees, MicroPort® is committed to its vision of building a People Centric Consortium of companies focused on Emerging Medical Technologies.
PRESS CONTACTS
ROBOCATH
Johanna Quast / Saffiyah Khalique
johanna@ala.associates / saffiyah@ala.associates
UK +44 1273 952 481 US +1 203 724 5950
